8-K
filed May 11, 2023, 7:59 PM ET
ticker GRCE
CIK 0001444192
other material
confidence high
sentiment neutral
materiality 0.80
Acasti Pharma appoints new CMO, VP Clinical Ops; terminates CFO and COOs; submits GTX-104 Phase 3 plan to FDA
Grace Therapeutics, Inc.
- Appointed Dr. R. Loch Macdonald as CMO, Carrie D'Andrea as VP Clinical Ops, Amresh Kumar as VP Program Mgmt; effective immediately or May 15.
- Terminated CFO Brian Ford (interim until June 30), COO Canada Pierre Lemieux, COO US George Kottayil; severance payments.
- Submitted full protocol for GTX-104 pivotal Phase 3 Safety Study to FDA; first patient dosing expected Q4 2023.
- Strategic realignment focuses on GTX-104; cash runway extended through Q2 2025; evaluating alternatives for GTX-102, GTX-101.
- Discontinuing Canadian operations, laying off substantially all workforce; rebuilding leaner US organization.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Brian Ford was terminated as Chief Financial Officer at Grace Therapeutics, Inc..
- Action
- terminated
- Role
- Chief Financial Officer
Exact text from the filing
On May 8, 2023, the Company terminated the employment of Brian Ford, Chief Financial Officer; Pierre Lemieux, Chief Operating Officer (Canada); and George Kottayil, Chief Operating Officer (US).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Amresh Kumar was appointed as VP of Program Management at Grace Therapeutics, Inc..
- Action
- appointed
- Role
- VP of Program Management
Exact text from the filing
On May 8, 2023, the Company appointed Amresh Kumar, PhD, as its VP of Program Management, effective May 15, 2023.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
George Kottayil was terminated as Chief Operating Officer (US) at Grace Therapeutics, Inc..
- Action
- terminated
- Role
- Chief Operating Officer (US)
Exact text from the filing
On May 8, 2023, the Company terminated the employment of Brian Ford, Chief Financial Officer; Pierre Lemieux, Chief Operating Officer (Canada); and George Kottayil, Chief Operating Officer (US).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. R. Loch Macdonald was appointed as Chief Medical Officer at Grace Therapeutics, Inc..
- Action
- appointed
- Role
- Chief Medical Officer
Exact text from the filing
On May 8, 2023, the Company appointed Dr. R. Loch Macdonald, MD, PhD, as Chief Medical Officer, effective immediately.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Pierre Lemieux was terminated as Chief Operating Officer (Canada) at Grace Therapeutics, Inc..
- Action
- terminated
- Role
- Chief Operating Officer (Canada)
Exact text from the filing
On May 8, 2023, the Company terminated the employment of Brian Ford, Chief Financial Officer; Pierre Lemieux, Chief Operating Officer (Canada); and George Kottayil, Chief Operating Officer (US).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Carrie D'Andrea was appointed as VP Clinical Operations at Grace Therapeutics, Inc..
- Action
- appointed
- Role
- VP Clinical Operations
Exact text from the filing
On May 8, 2023, the Company appointed Carrie D'Andrea as its VP Clinical Operations, effective immediately.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.